CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
modified Hyper-CVADdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00581854
NCT00581854Phase 2Completed
CompareCT.gov

Phase II Pilot Study of Hyper-CVAD Plus Rituximab for Previously Untreated Mantle Cell Lymphoma

University of Wisconsin, Madison·interventional·Posted Dec 28, 2007·Updated Dec 13, 2019

In Brief

A Phase 2 clinical trial evaluating modified Hyper-CVAD for Mantle Cell Lymphoma. Completed, enrolled 22 participants across 1 site.

Detailed Summary

rituximab and modified (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMantle Cell Lymphoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 28, 2007
Enrollment StartJun 1, 2000
Primary CompletionJun 1, 2006
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6 yearsPosted 18.5 years ago

Interventions

modified Hyper-CVADdrug

rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years